货号（Catalog No.）

CSD00004

通用名INN

Bevacizumab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer PH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab, a humanized monoclonal antibody,specifically binds to all VEGF-A isoforms with high affinity.

别名(Alternative names)

12-IgG1,F(ab)-12 IgG1,Fab-12 IgG1,rhuMAb-VEGF

靶点;物种(Specificity target name;species)

VEGFA[Homo sapiens]

活性研究（体外/体内研究）(Activity in vitro)

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.

种类(Species)

Humanized

受体鉴定(Receptor identification)

IgG1-kappa

化学信息

分子量(MV)

149000.00 Da

CAS

216974-75-3

存储条件(Storage)

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.

Note

For research use only .